Cadence Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cadence Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,729	Closed	-$853K	–	344
2020 Q2	$853K	Hold	7,729	–	–	0.12%	246
2020 Q1	$771K	Sell	7,729 -199	-3%	-$25.7K	0.13%	245
2019 Q4	$1.18M	Sell	7,928 -160	-2%	-$21.8K	0.13%	228
2019 Q3	$1.04M	Sell	8,088 -164	-2%	-$22K	0.15%	251
2019 Q2	$1.18M	Buy	+8,252	New	+$1.11M	0.12%	245
2018 Q4	–	Sell	-1,567	Closed	-$263K	–	534
2018 Q3	$263K	Buy	+1,567	New	+$269K	0.01%	603
2013 Q3	–	Sell	-129,346	Closed	-$8.89M	–	622
2013 Q2	$8.89M	Buy	+129,346	New	+$7.91M	0.42%	110

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Cadence Capital Management's JAZZ Position: Q3 2020 in Review

Cadence Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2020, closing a stake of 7,729 shares — an estimated $853K sold.

Cadence Capital Management first reported a position in JAZZ in Q2 2013 and held it in 7 quarters. The position peaked at $8.89M in Q2 2013. 390 funds tracked by Wall St. Rank hold JAZZ as of Q3 2020.

Cadence Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Cadence Capital Management sold 7,729 Jazz Pharmaceuticals shares in Q3 2020, an estimated $853K.
Cadence Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Cadence Capital Management's Jazz Pharmaceuticals position peaked at $8.89M in Q2 2013.
390 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.